Please complete the form here or contact licensing@endocrine.org to learn more about licensing content from the Endocrine Society.

If you believe you should have access to this media, please login.

CAM2029 Octreotide Subcutaneous Depot Maintains Control of IGF-I and Symptoms of Acromegaly Across the 4-Week Dosing Interval and During Intervals Greater Than 28 Days: Data from the ACROINNOVA 1 Trial

Related Media